Key result
This review provides an evidence-based approach to the diagnostic and therapeutic implications of advanced age in the evaluation and management of stable ischemic heart disease in older adults.
Why the study?
Elderly patients, particularly those aged 75 or older, are underrepresented in trials informing ischemic heart disease guidelines, leaving the risk-benefit ratios of guideline-based pharmacotherapies and percutaneous coronary interventions poorly defined.
This review provides an evidence-based approach to the diagnostic and therapeutic management of stable ischemic heart disease in elderly patients, a population often underrepresented in clinical trials.
Demographic trends worldwide show a progressively aging population and an increase in the overall medical complexity of elderly patients with cardiovascular disease. Elderly patients, especially those aged 75 or older, are relatively underrepresented in many of the clinical trials that helped create major society guidelines for evaluation and management of ischemic heart disease. Consequently, risk benefit ratios of a guideline-based approach in these patients are not well defined, especially with regards to pharmacotherapies and percutaneous coronary interventions. In this article we offer a practical approach to defining the elderly population, and provide an evidenced based review of the diagnostic and therapeutic implications of advanced age in the evaluation and management of ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Juan Vilaro (2019) conducted a review in Stable Ischemic Heart Disease. Evaluation and management of ischemic heart disease was evaluated. This review provides an evidence-based approach to the diagnostic and therapeutic implications of advanced age in the evaluation and management of stable ischemic heart disease in older adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: